Core Insights - Hyperscale Data, Inc. has reported a significant increase in its Bitcoin holdings, growing approximately 30% from the previous week, with a total Bitcoin treasury valued at around $68.8 million as of October 26, 2025, representing about 50% of the company's market capitalization [1][2][4] Group 1: Bitcoin Holdings and Strategy - The company's subsidiary, Sentinum, holds approximately 194.5513 Bitcoin, with a market value of about $22.3 million based on the Bitcoin price of $114,472 on October 26, 2025 [2] - Hyperscale Data has allocated $46.5 million in cash for Sentinum to invest in open-market Bitcoin purchases, employing a disciplined dollar-cost averaging strategy to mitigate short-term market volatility [3][4] - The company acquired approximately $4.6 million of Bitcoin in the past week, capitalizing on recent price pullbacks to improve its long-term average cost of Bitcoin [4] Group 2: Mining Operations and Future Plans - Hyperscale Data has announced the purchase of over 2,000 new Bitmain S21+ Bitcoin miners, indicating a substantial investment in its Bitcoin mining operations to support its goal of accumulating $100 million in Bitcoin [4] - The company plans to continue issuing weekly reports detailing its Bitcoin holdings as it progresses towards its $100 million digital asset treasury target [5] Group 3: Company Structure and Divestiture - Hyperscale Data operates through its wholly owned subsidiary Sentinum, which mines digital assets and provides colocation and hosting services [7] - The company anticipates a divestiture of Ault Capital Group, Inc. in the second quarter of 2026, which will allow it to focus on high-performance computing services and digital asset holdings [8]

Core Insights - Solana Company has entered into agreements with Helius and Twinstake for non-custodial staking services, enhancing its digital asset treasury strategy [1][3] - The partnerships aim to maximize on-chain yield in a secure and compliant manner, reinforcing the company's commitment to the Solana network's long-term growth [3][4] Company Developments - The Providers will offer services including staking, voting with staked tokens, and reporting on staked tokens, which will strengthen the operational backbone of Solana Company's SOL holdings [2][3] - Helius, a leading validator, has over 13 million SOL staked and provides institutional-grade staking services, while Twinstake and Anchorage Digital contribute regulated and enterprise-level staking capabilities [3][4] Industry Context - Solana is recognized as the fastest-growing blockchain, processing over 3,500 transactions per second and having around 3.7 million daily active wallets, with more than 23 billion transactions year-to-date [4] - The network offers a native staking yield of approximately 7%, positioning it as a financially productive asset compared to non-yield-bearing assets like Bitcoin [4]

As filed with the Securities and Exchange Commission on October 14, 2025 Registration No. 333-290133 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DEFI DEVELOPMENT CORP. (Exact name of registrant as specified in its charter) Delaware 7389 83-2676794 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on October 14, 2025 Registration No. 333-290297 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DEFI DEVELOPMENT CORP. (Exact name of registrant as specified in its charter) Delaware 7389 83-2676794 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

Core Insights - Predictive Oncology Inc. has appointed Shawn Matthews, Thomas McLaughlin, and Sara Turken to its leadership team and Board of Directors to support its new digital asset treasury strategy focused on the Aethir (ATH) token [1][2][3] Leadership Appointments - Shawn Matthews, CEO of DNA Holdings Venture, Inc. and former CEO of Cantor Fitzgerald, joins the Board of Directors [2][3] - Thomas McLaughlin, CIO of DNA Holdings Venture, Inc., is appointed as Chief Investment Officer [2][4] - Sara Turken, JD, a biopharmaceutical veteran, is appointed as General Counsel [2][5] Strategic Focus - The company is leveraging its AI-driven drug discovery capabilities to implement an innovative digital treasury asset strategy, which aims to address its AI requirements and capitalize on the growing global need for AI infrastructure [3][8] - Predictive Oncology operates a digital asset treasury focused on the Aethir (ATH) token, creating the world's first Strategic Compute Reserve [8] Company Background - Predictive Oncology utilizes AI and machine learning to expedite early drug discovery, with its platform, PEDAL, achieving 92% accuracy in predicting tumor responses to drug compounds [6][7] - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [7]

Group 1 - ENDRA Life Sciences Inc. announced an aggregate of $4.9 million in commitments for a private placement led by institutional and cryptocurrency investors [1] - The proceeds from the offering will be utilized to launch a diagnostic tool for monitoring metabolic dysfunction associated liver disease (MASLD) and metabolic dysfunction associated steatohepatitis (MASH) [1]

Core Insights - Sharps Technology, Inc. has announced a strategic collaboration with Coinbase to expand its Solana digital asset treasury strategy, having acquired over 2 million SOL valued at over $400 million [1][2]. Group 1: Company Strategy - The collaboration with Coinbase aims to leverage its digital asset treasury strategy to advance decentralized finance [2]. - STSS plans to utilize Coinbase Prime's custody infrastructure and OTC desk products as part of this partnership [2]. - The partnership highlights STSS's commitment to supporting the global adoption of digital assets and working with secure, regulated service providers [2]. Group 2: Financial Position - STSS has acquired over 2 million SOL, currently valued at over $400 million, with SOL trading at over $210 [1]. - The company is focused on accumulating SOL, the native digital asset of the Solana blockchain, to power on-chain yield generation [6].

Core Insights - Caliber has reported substantial improvements in its balance sheet, liquidity position, and stockholders' equity due to its Digital Asset Treasury (DAT) strategy [2][3] - The company raised approximately $28.9 million in new equity, significantly enhancing its financial standing and reducing stockholders' deficit [2][3] Financial Performance - Estimated cash for Q3 2025 is projected to be between $10.0 million and $11.0 million, a significant increase from $0.6 million in Q2 2025 [2] - LINK Treasury is estimated to be between $9.0 million and $10.0 million, compared to no holdings in Q2 2025 [2] - Total new equity raised includes $13.0 million in common stock and $15.9 million in Series B preferred stock, netting $26.2 million after equity issuance costs [2] Strategic Initiatives - The DAT strategy involves disciplined, dollar-cost-averaged purchases of Chainlink ($LINK) to capture long-term appreciation and staking yield [3] - Caliber aims to create one of the largest LINK treasuries held by a public company, enhancing its balance sheet and liquidity options [4][3] - This strategy positions Caliber at the intersection of real asset infrastructure and digital asset infrastructure, providing transparent participation in the LINK ecosystem [3] Company Overview - Caliber is an alternative investment manager with over $2.9 billion in managed assets and a 16-year track record in private equity real estate investing [7] - The company became the first U.S. public real estate platform to launch a Digital Asset Treasury strategy anchored in Chainlink in 2025 [7]

Core Insights - Predictive Oncology has successfully closed two private investment in public equity transactions (PIPEs) totaling approximately $343.5 million to support its digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem [1][2] Investment Details - The PIPEs consist of two components: - A cash PIPE raising approximately $50.8 million through the sale of about 4.4 million shares of common stock at a price of $11.6265 per share [2] - A crypto PIPE involving pre-funded warrants to purchase up to approximately 14.9 million shares of common stock for a purchase price of $11.6165 per warrant, in exchange for approximately $292.7 million in notional value of ATH contributions [2] - The PIPEs closed on October 7, 2025, and the pre-funded warrants will be exercisable following shareholder approval [2][4] Strategic Intent - The company aims to utilize the in-kind contribution of ATH to fund its digital asset treasury strategy and acquire ATH in the open market, alongside working capital and general corporate purposes [4] - The investment aligns with the company's computational needs and capital requirements as it seeks to lead in AI-driven drug discovery [5] Company Background - Predictive Oncology leverages AI and machine learning for drug discovery, with its platform, PEDAL, achieving 92% accuracy in predicting tumor responses to drug compounds [9] - The company has a biobank of over 150,000 tumor samples, enhancing its AI-based drug discovery capabilities [9] Aethir Overview - Aethir is a decentralized physical infrastructure network providing GPU resources for AI computation, gaming, and cloud workloads, aiming to democratize access to AI infrastructure [7][8] - ATH serves as a utility token within the Aethir ecosystem, facilitating GPU rentals, staking, and rewards [8]

Core Insights - MAIA Biotechnology has authorized the allocation of up to 90% of its liquid assets in cryptocurrencies, specifically Bitcoin (BTC), Ethereum (ETH), and USD Coin (USDC) [1][2] - The company aims to diversify its investment portfolio through a new digital asset treasury strategy, focusing on high-quality cryptocurrency tokens to minimize risk while seeking strong returns [3] Group 1: Digital Asset Strategy - The Board of Directors has approved a strategy to hold a significant portion of liquid assets in cryptocurrencies, with corporate officers authorized to manage these transactions [2] - MAIA's CEO emphasized a disciplined approach to investing in cryptocurrencies, targeting only the highest-quality tokens to enhance shareholder value while maintaining adequate working capital [3] Group 2: Company Overview - MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO) for treating NSCLC patients [4]